Biomea Fusion Company Insiders
| BMEA Stock | USD 1.22 -0.03 -2.40% |
Biomea Fusion employs about 42 people. The company is managed by 14 executives with a total tenure of roughly 98 years, averaging almost 7.0 years of service per executive, having 3.0 employees per reported executive. A leadership review of Biomea Fusion matters because management quality often shapes how effectively strategy is translated into revenue growth, margins, and cash generation. The better read usually comes from comparing management claims with operating results, tenure stability, and capital-allocation outcomes over time.
Management Team Effectiveness
The company has return on total asset (ROA) of -75.22 % which means that it is not converting its asset base into profit. This is a lagging result relative to sector standards. Similarly, it shows a return on stockholder's equity (ROE) of -209.0 %, which means that it produced no profit with money invested by stockholders.As of March 18th, 2026, Common Stock Shares Outstanding is anticipated to decline to approximately 26.5 M. In addition to that, Net Loss is estimated to rise to approximately -70 M.
Stock Institutional Investors
Biomea Fusion has 38.19% institutional ownership and 7.30% insider stake. Revenue scale should be reviewed against peers and reporting history. This mix shapes how the stock trades around earnings. The business currently sits in the Health Care sector and the Pharmaceuticals, Biotechnology & Life Sciences industry. Watching turnover and volume trends alongside ownership data adds depth to the picture.
| Shares | Renaissance Technologies Corp | 2025-12-31 | 478.6 K | Susquehanna International Group, Llp | 2025-12-31 | 478 K | Morgan Stanley - Brokerage Accounts | 2025-09-30 | 443.1 K | Two Sigma Investments Llc | 2025-12-31 | 423.5 K | The Goldman Sachs Group Inc | 2025-09-30 | 266 K | Xtx Topco Ltd | 2025-09-30 | 265.3 K | Superstring Capital Management Lp | 2025-09-30 | 250 K | Northern Trust Corp | 2025-09-30 | 187.6 K | State Street Corp | 2025-09-30 | 140.1 K | Fmr Inc | 2025-12-31 | 8.8 M | Cormorant Asset Management, Llc | 2025-09-30 | 3.6 M |
Insider Trading Activities
Insider disclosures for Biomea Fusion show how people closest to the business are behaving as market expectations change. Most U.S. insider trades appear in Form 4 filings. The value comes from reading the sequence, not one filing in isolation.
Outstanding Bonds
Outstanding bonds linked to Biomea Fusion can tell investors a great deal about how the company finances itself beyond common equity markets. Used together with earnings and cash-flow analysis, the bond stack can reveal whether leverage is a manageable tool or a developing constraint.
About 30% of Biomea Fusion outstanding shares are owned by institutional investors. Institutional investors - such as mutual funds, pension funds, and asset managers - typically hold positions as part of a broader portfolio strategy, managing assets on behalf of clients. As a result, institutional investors are subject to reporting requirements and oversight rules - such as 13F filings - that differ from those for individual retail investors. Changes in institutional ownership of Biomea Fusion can sometimes signal a shift in professional sentiment toward the company. Institutions collectively hold about 38% of Biomea Fusion's shares, insiders own approximately 7%, and the remaining 55% is in public hands. Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 40.6 M | Current Value 40.6 M | Average Shares Outstanding 29.8 M | Quarterly Volatility 8.7 M |
Macro event markers
Holders Distribution
Institutional investors in Biomea Fusion typically operate with more research capacity, technology, and trading scale than retail holders, which is why their activity can materially affect price behavior. The opportunity for retail investors is not to imitate blindly, but to understand how large-holder positioning may affect liquidity, volatility, and timing.
Market Cap and Value
Workforce Comparison
Biomea Fusion is rated below average in number of employees among leading competitors. The total workforce of Health Care industry is currently estimated at about 1,020. Biomea Fusion holds roughly 42.0 in number of employees claiming about 4% of equities under Health Care sector.
Insider Trading History
The insider timeline for Biomea Fusion shows how management behavior has tracked against the stock's price over time. Investors focus on trades outside normal pay timelines, as those are more likely to reflect genuine conviction.
Notable Stakeholders
Reviewing the stakeholders around Biomea Fusion can help investors understand which people or institutions may influence direction, governance, and strategic pressure. Used properly, stakeholder review helps investors stay aware of the people and incentives that may be shaping key decisions behind the scenes.
| Franco CPA | CFO Officer | Profile | |
| Michael Hitchcock | Interim Director | Profile | |
| Juan MD | Chief Officer | Profile | |
| Caroline Dupont | Senior Contracts | Profile | |
| Stephan MD | Chief Officer | Profile | |
| Franco Valle | CFO Officer | Profile | |
| Ravi Upasani | Executive Property | Profile | |
| Ramses Erdtmann | President, CoFounder | Profile | |
| Thomas Butler | Chairman CoFounder | Profile | |
| Thorsten Kirschberg | Executive Chemistry | Profile | |
| Alex Cacovean | Vice Sciences | Profile | |
| Naomi Cretcher | Chief Officer | Profile | |
| Heow Tan | Chief Officer | Profile | |
| Caroline JD | Senior Contracts | Profile |
Management Information & Data Sources
Biomea Fusion is a micro-cap company in Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care. Executive review focuses on insiders, senior management, and employee signals. Employee count and organizational scale can help frame operating leverage and execution complexity. Biomea Fusion employs 42 people.
This section for Biomea Fusion is built from periodic company reporting and market reference feeds, with harmonization applied to align reporting definitions. Values may update on different source schedules. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Workforce metrics tied to Biomea Fusion offer a useful way to test whether headcount and economic output are moving in a productive direction. The business is commonly classified in the Healthcare sector and the Biotechnology industry.
Biomea Fusion Manpower Efficiency
Return on Biomea Fusion Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.3M | |
| Net Loss Per Executive | 9.9M | |
| Working Capital Per Employee | 1.1M | |
| Working Capital Per Executive | 3.3M |
Popular Tools for Biomea Stock analysis
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |